Best Telehealth Clinics in Arizona (2026)

Arizona has one of the most permissive telehealth laws in the country. HB 2454, signed by Governor Ducey on May 5, 2021, made the COVID-era telehealth executive order (Executive Order 2020-15, issued March 25, 2020) permanent. It was described at the time as "the broadest telehealth law in the nation." The law is codified at ARS §§ 36-3601 through 36-3607.

ARS § 36-3602(F) explicitly prohibits state regulatory boards from enforcing in-person exam requirements before prescribing via telehealth, except for Schedule II controlled substances. For Schedule II drugs, an in-person or audio-visual examination is required, but video telehealth satisfies this. For all other controlled substances (Schedule III through V, including testosterone), there is no in-person requirement at all. This statutory prohibition on board-imposed in-person requirements is stronger than what most states offer.

Arizona also has a unique interstate telehealth registration pathway under ARS § 36-3606. Out-of-state providers can register to serve Arizona patients without obtaining a full Arizona license. This is separate from the IMLC and is unique to Arizona among the states we cover.

Arizona is an active IMLC member as well, giving the state two separate pathways for out-of-state provider access. A Telehealth Advisory Committee on Best Practices (established by ARS § 36-3607) issues practice guidelines that providers must follow. Insurance coverage parity is at ARS § 20-1057.13. The patient's home was added as an eligible originating site for telehealth in fall 2024.

The federal DEA waiver through December 2026 provides additional federal authority for Schedule II through V telehealth prescribing. Arizona's own state law already permits Schedule III through V without an in-person visit regardless of the federal waiver.

Arizona has 7.2 million residents and is the fourteenth-largest state. Provider availability is among the highest in the country, supported by the state's permissive telehealth laws, IMLC membership, and the unique interstate registration pathway. Of the 64 providers tracked, roughly 58 serve Arizona.

All major TRT providers serve Arizona. Maximus ($100/mo, all 50 states), Hone Health ($25/mo entry, all 50 states), TRT Nation ($99/mo, 45 states including AZ), BraverX ($129/mo), PeterMD ($99/mo annual), DudeMeds ($77/mo), Titan Medical ($99/mo), and Feel30 ($99/mo, if AZ is not in their exclusion list) are available. Defy Medical and Marek Health serve "Most US states."

GLP-1 availability is fully unrestricted. Embody, SkinnyRx, DirectMeds, Zealthy, Remedy Meds, GobyMeds, Sesame Care, MEDVi, Shed, Sunlight, Fridays, and Mochi Health all serve Arizona. No semaglutide or tirzepatide access issues at the state level.

All HRT, hair loss, and ED providers serve Arizona. Midi Health accepts insurance. PlushCare accepts major insurers. Strut Health serves "Most US states (excl. AK)" so AZ is covered. The interstate registration pathway means even smaller providers can serve AZ patients without full licensure.

An Arizona compounding facility in Phoenix received an FDA warning letter in April 2025 for semaglutide and tirzepatide compounding violations, suggesting active federal enforcement in-state. This does not restrict patient access but affects local compounders.

TRT pricing matches national rates. DudeMeds: $77/mo ($1,124/year). TRT Nation: $99/mo ($1,446/year). PeterMD: $99/mo annual ($1,188/year). Maximus: $100/mo annual ($1,300/year). Titan Medical: $99/mo ($1,417/year). BraverX: $129/mo ($1,548/year). Defy Medical: $200/mo ($2,800/year).

GLP-1 ranges from $99/mo to $399/mo. GobyMeds at $119/mo and Fridays at $117/mo are budget options. Median is $179/mo.

AHCCCS (Arizona Medicaid) does not cover GLP-1s when the sole indication is weight loss or obesity. Required coverage exists for Wegovy for cardiovascular disease and Zepbound for obstructive sleep apnea as federally mandated. AHCCCS spends approximately $73 million on GLP-1s total, primarily for diabetes, with about $13 million from the state general fund. Legislative committee hearings in 2024 and 2025 examined expanding obesity coverage, but no legislation was enacted.

Arizona does not tax prescription medications. The state sales tax (TPT) is 5.6% (plus local) but Rx drugs are exempt. Arizona has no state income tax for individuals earning under certain thresholds (flat 2.5% otherwise).

HRT: Midi Health (insurance), PlushCare ($20/mo), Evernow ($35/mo), Alloy ($49/mo). ED: Hims $17/mo to MEDVi $119/mo. Hair loss: Hims $20/mo to Nutrafol $88/mo.

TRT (testosterone replacement therapy)

Arizona is one of the best states for telehealth TRT. ARS § 36-3602(F) prohibits regulatory boards from imposing in-person requirements for non-Schedule II prescriptions. Testosterone (Schedule III) can be prescribed via telehealth with no in-person visit under state law alone, independent of the federal DEA waiver. Both compounded and FDA-approved testosterone are available. The interstate registration pathway (ARS § 36-3606) gives Arizona patients access to providers who may not have full AZ licenses.

GLP-1 weight loss

No state-specific restrictions on semaglutide or tirzepatide. Federal FDA compounding rules apply. An Arizona compounding facility received an FDA warning letter in April 2025, suggesting active enforcement. AHCCCS does not cover weight-loss GLP-1s. No state-specific compounding restrictions beyond the federal framework.

HRT (hormone replacement therapy)

HRT follows standard federal prescribing rules in Arizona. No additional state restrictions apply. The ARS § 36-3602(F) prohibition on board-imposed in-person requirements benefits HRT prescribing as well.

Hair loss

Hair loss treatment follows standard federal prescribing rules in Arizona. No additional state restrictions apply.

ED (erectile dysfunction)

ED treatment follows standard federal prescribing rules in Arizona. No additional state restrictions apply.

Peptides

Peptide therapy follows standard federal rules in Arizona. The board prohibition on in-person requirements (ARS § 36-3602(F)) applies to non-Schedule II peptide prescriptions. Maximus and Defy Medical serve Arizona. The interstate registration pathway may bring additional peptide providers into the state.